Skyrizi (risankizumab-rzaa)

**Product type:** Human Prescription Drug

**Active ingredient:** RISANKIZUMAB

**Strength:** 180 mg/1.2mL

**Dosage form:** Injection

**Route:** Subcutaneous

**Labeler:** AbbVie Inc.

**Marketing category:** BLA (BLA761105)

**Pharmacologic class:** Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA]